Avalon GloboCare (NASDAQ: AVCO), a clinical-stage global developer of cell-based technologies and therapeutics, has expanded and filed two provisional patents with the U.S. Patent and Trademark Office. A result of Avalon’s AVA-Trap(TM) therapeutic program, the patents outline compositions and methods of developing a decoy cytokine receptor-based filter system to treat cytokine storms, a life-threatening condition that can cause multi-organ failure and death. “We are grateful for our strong scientific partnerships that enabled the rapid speed with which we are developing this novel clinical tool,” said Avon president and CEO Dr. David Jin in the press release. “This medical device holds enormous promise as it directly addresses a leading cause of mortality for patients with illnesses that make them vulnerable to the damaging effects of a cytokine storm.”
To view the full press release, visit http://nnw.fm/kB1BX
About Avalon GloboCare Corp.
Avalon GloboCare is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX(TM)) and regenerative therapeutics. For more information about the company, visit www.avalon-globocare.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork